A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265).
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Georgina V. Long, Reinhard Dummer, Antoni Ribas, Igor Puzanov, Olivier Michielin, Ari M. Vanderwalde, Robert Hans Ingemar Andtbacka, Jonathan S. Cebon, Eugenio Fernandez, Josep Malvehy, Anthony J. Olszanski, Thomas Gajewski, John M. Kirkwood, Olga Kuznetsova, Lisa Chen, Scott J. Diede, Jeffrey Chou, F. Stephen Hodi
Institutions: The University of Sydney, Melanoma Institute Australia, University Hospital Zurich, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Vanderbilt University Medical Center, Centre Hospitalier Universitaire Vaudois, University of Utah, Huntsman Cancer Institute, Austin Hospital, Ludwig Cancer Research, University Hospital of Geneva, Hospital Clínic de Barcelona, Fox Chase Cancer Center, University of Chicago, University of Pittsburgh Medical Center, Merck & Co., Inc., Rahway, NJ, USA (United States), Amgen (United States), Dana-Farber Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891708681